Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: Case examples from acute stroke and stroke prevention

International Journal of Stroke

Volumn 6, Issue 6, 2011, Pages 472-479

  Bath, Philip ^a   Hogg, Cheryl ^a   Tracy, Michael ^a   Pocock, Stuart ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Acute stroke; Methodology; Numbers needed to treat; Randomized controlled trial; Rehabilitation; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; TIRILAZAD;

ACUTE DISEASE; ANALYTICAL PARAMETERS; ARTICLE; CALCULATION; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CRANIECTOMY; DISEASE SEVERITY; HEALTH CARE UTILIZATION; HUMAN; NUMBER NEEDED TO TREAT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE;

AGED; ALGORITHMS; ASPIRIN; CLINICAL TRIALS AS TOPIC; CONFIDENCE INTERVALS; DIPYRIDAMOLE; DRUG COMBINATIONS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; RESEARCH DESIGN; SAMPLE SIZE; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 82255192780     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00614.x     Document Type: Article

References (32)

1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728-33.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med 1995; 333:1581-7.
3. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical re-analysis of functional outcomes in stroke trials. Stroke 2007; 38:1911-5.
4. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. Int J Stroke 2008; 3:78-84.
5. Bath PMW, Geeganage CM, Gray LJ, Collier T, Pocock S. Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published stroke trials. Stroke 2008; 39:2817-23.
6. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001; 20:3947-62.
7. Liang BA, Lew R, Zivin JA. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues. Arch Neurol 2008; 65:1429-33.
8. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Arch Neurol 2004; 61:1066-70.
9. Saver JL. Clinical impact of nxy-059 demonstrated in the saint i trial: derivation of number needed to treat for benefit over entire range of functional disability. Stroke 2007; 38:1515-8.
10. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 2007; 38:2279-83.
11. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin scale. Stroke 2009; 40:2079-84.
12. Musch BC, Naberhuis-Stehouwer SA, Brosse D, Peters GR. An International, Randomized, Vehicle Controlled Trial of the Efficacy of Tirilazad Mesylate in Patients with Acute Ischemic Stroke (tess ii) (Protocol m/2700/0088). Kalamazoo: Pharamcia & Upjohn, 1997.
13. Vahedi K, Hofimeijer J, for the DECIMAL DaHi et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6:215-22.
14. International Stroke Trial Collaborative Group. The international stroke trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349:1569-81.
15. Juby LC, Lincoln NB, Berman P, Group ftSUES. The effect of a stroke rehabilitation unit on functional and psychological outcome: a randomised controlled trial. Cerebrovasc Dis 1996; 6:106-10.
16. Lincoln NB, Husbands S, Trescoli C, Drummond AER, Gladman JRF, Berman P. Five year follow up of a randomised controlled trial of a stroke rehabilitation unit. BMJ 2000; 320:549.
17. Stevens RS, Ambler NR. The dover stroke rehabilitation unit: a randomised controlled trial of stroke management; in Rose FC (ed): Advances in Stroke Therapy. New York: Raven Press, 1982: 257-61.
18. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
19. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Should stroke trials adjust functional outcome for baseline prognostic factors? Stroke 2009; 40:888-94.
20. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 2000; 31:2257-65.
21. Bath PM, Iddenden R, Bath FJ, Orgogozo JM, Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev 2001: 002087.
22. Leonardi-Bee J, Bath PM, Dipyridamole in Stroke Collaboration (DISC) et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36:162-8.
23. Kosanke J, Bergstralh E. Gmatch, 2004. Available at (Last accessed 24 March 2009).
24. Murray GD, Barer D, Choi S et al. Design and analysis of phase iii trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma 2005; 22:511-7.
25. Saver JL. Novel-end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007; 38:3055-3062.
26. Saver J, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2008; 72:1310-5.
27. Lees KR, Zivin JA, For the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trail Investigators et al. Nxy-059 for acute ischemic stroke. N Eng J Med 2006; 354:588-99.
28. Shuaib A, Lees KR, for the SAINT II Trial Investigators et al. Nxy-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357:562-71.
29. Hacke W, Kaste M, ECASS Investigators et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-29.
30. Guyatt GH, Juniper EF, Walter DS, Griffiths LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ 1998; 316:690-3.
31. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Chapter 12. New York: John WIley & Sons Inc, 1982.
32. Lindley RI, Waddell F, Livingstone M et al. Can simple questions assess outcome after stroke? Cerebrovasc Dis 1994; 4:314-2.